Geron Earnings Call: Rytelo Growth Amid Profit Pressures

Geron Corporation ((GERN)) has held its Q4 earnings call. Read on for the main highlights of the call.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Geron’s latest earnings call painted a cautiously optimistic picture, with strong commercial momentum for Rytelo offset by lingering profitability and pricing headwinds. Management emphasized robust revenue growth, expanding prescriber adoption, and clearer visibility into 2026, even as cash burn, gross‑to‑net erosion, and European uncertainty tempered the bullish narrative. Explosive Full-Year Revenue Growth from First Full Rytelo Launch Total net revenue surged to $184 million in 2025 from $76 million in 2024, marking roughly 142% year‑over‑year growth as Rytelo completed its first full commercial year. The jump underscores rapid uptake in lower‑risk myelodysplastic syndromes and validates the drug as the core of Geron’s business model. Q4 Demand and Prescriber Expansion Confirm Commercial Traction Rytelo generated $48 million in Q4 net revenue, in line with internal expectations and showing sustained momentum into year‑end. Demand rose 9% quarter‑over‑quarter, while prescribing accounts expanded about 13% to roughly 1,300, as Geron added around 150 new customer sites in the period. 2026 Revenue Guidance Signals High-Teens to Mid-20s Growth Management reaffirmed 2026 Rytelo net revenue guidance of $220 million to $240 million, implying about 25% growth at the midpoint over 2025 levels. They expect the bulk of that increase to land in the second half of 2026, reflecting a maturing base of prescribers and more focused commercial execution. Targeted Second-Line Strategy Anchored in 8,000-Patient U.S. Market Geron is concentrating on eligible second‑line lower‑risk MDS patients in the U.S., which it pegs at roughly 8,000 individuals. The company noted that about 30% of Rytelo patient starts are currently in first‑ and second‑line settings on a rolling 12‑month basis, highlighting room to deepen penetration in its core segment. Pipeline and Real-World Data Bolster Long-Term Clinical Story Clinically, the IMPACT MF trial is fully enrolled, with an interim overall survival analysis expected after a death‑event trigger in the second half of 2026 and a final readout planned for 2028. Geron is also backing more than 10 investigator‑sponsored trials and real‑world evidence initiatives, with the first meaningful real‑world data expected to emerge in 2026. Cost Discipline Aims to Bend the Expense Curve in 2026 The company guided 2026 operating expenses to a range of $230 million to $240 million, about $20 million lower at the midpoint than the $255 million spent in 2025. That pullback reflects tighter R&D and SG&A management while still funding targeted commercial investments to support Rytelo’s growth trajectory. Cash Position Solid but Declining, with Added Financing Flexibility Geron closed 2025 with roughly $400 million in cash, cash equivalents, restricted cash and marketable securities, down from $503 million a year earlier. To bolster flexibility, it amended its Pharmakon loan to preserve access to up to $125 million in additional capital through mid‑2026 and plans a new shelf and at‑the‑market program. Operating Loss Highlights the Path to Scale Is Still Unfinished Despite strong sales growth, Geron remained unprofitable at the operating level in 2025, as $255 million in operating expenses exceeded $184 million in revenue by about $71 million. Management reiterated that there is a path to profitability but signaled ongoing investment in commercialization and clinical work as near‑term priorities. Cash Burn and Gross-to-Net Trends Add to Margin Pressure Cash fell by roughly $103 million year‑over‑year, a decline of about 20.5%, underscoring continuing cash burn as the company scales. Gross‑to‑net deductions climbed to 17.7% in 2025 from 14.5% in 2024 and are expected to remain in the high teens to low 20s in 2026, which could cap net revenue realization even as volume grows. SG&A Growth, Restructuring and Channel Mix Shape Profitability Outlook Selling, general and administrative expenses rose to $159 million from $146 million, driven mainly by sales force expansion and marketing needed for Rytelo’s ramp. A December 2025 restructuring and workforce reduction brought one‑time charges and some near‑term disruption, while rising 340B utilization and broader GPO contracting contributed to higher discounts. European Pricing and Access Cloud Ex-U.S. Upside While Rytelo is approved in Europe, management signaled limited near‑term contribution from that region due to uncertain health‑technology assessments, funding pathways and Most‑Favored‑Nation pricing rules. Investors should not expect meaningful ex‑U.S. revenue until Geron secures attractive access terms or partners in key European markets. Guidance and Outlook: Growth Focus, Gradual Path Toward Profitability For 2026, Geron is modeling Rytelo revenue of $220 million to $240 million, supported by steady quarter‑over‑quarter demand growth and deeper penetration in the 8,000‑patient U.S. second‑line MDS market. Operating expenses are guided to $230 million to $240 million, R&D and SG&A are trending more disciplined, and management plans to keep funding real‑world data and ISTs while emphasizing that profitability remains a medium‑term goal. Geron’s earnings call framed a story of strong top‑line expansion and advancing clinical assets, balanced against persistent losses and intensifying pricing pressure. For investors, the key watchpoints will be execution on the second‑line strategy, discipline on spending, stability in gross‑to‑net, and any incremental clarity on European access and the timing of a shift toward sustainable profitability.